Inclusion Criteria:

• Patients who have a life expectancy of at least 12 weeks
• Patients with advanced HCC (unresectable, and/or metastatic) which has been histologically or cytologically documented
• Patients must have at least one tumor lesion that meets both of the following criteria: 1) can be accurately measured in at least one dimension according to RECIST; 2) has not been previously treated with local therapy
• Patients who have received local therapy except chemoembolization, such as surgery, radiation therapy, hepatic arterial embolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation are eligible, provided that they either have a target lesion which has not been subjected to local therapy and/or the target lesion(s) within the field of the local therapy has shown an increase of 25% in the size. Local therapy must be completed at least 4 weeks prior to the baseline scan
• Patients who have an ECOG performance status of 0, 1, or 2

Exclusion Criteria:

• Previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (Ta, Tis & T1). Any cancer curatively treated > 3 years prior to entry is permitted
• History of cardiac disease
• Serious myocardial dysfunction
• Active, clinically serious infections
• Known history of HIV infection
• Known CNS tumors including metastatic brain disease
• Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry